On June 2, 2025, renowned analyst Ami Fadia from Needham issued a rating update for Blueprint Medicines (BPMC, Financial). The stock's rating was downgraded from "Buy" to "Hold".
Despite the downgrade in rating, Needham maintained its price target for Blueprint Medicines (BPMC, Financial) at $130.00 USD. This unchanged target reflects the analysts' stable outlook on the company's market performance in the short term.
The decision to downgrade Blueprint Medicines (BPMC, Financial) by Needham reflects a shift in the firm's assessment of the stock’s potential under current market conditions. Investors in BPMC should note the updated rating while formulating their investment strategies.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 16 analysts, the average target price for Blueprint Medicines Corp (BPMC, Financial) is $122.00 with a high estimate of $150.00 and a low estimate of $83.00. The average target implies an upside of 20.37% from the current price of $101.35. More detailed estimate data can be found on the Blueprint Medicines Corp (BPMC) Forecast page.
Based on the consensus recommendation from 19 brokerage firms, Blueprint Medicines Corp's (BPMC, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Blueprint Medicines Corp (BPMC, Financial) in one year is $191.68, suggesting a upside of 89.13% from the current price of $101.35. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Blueprint Medicines Corp (BPMC) Summary page.
